Loading people...
Darrin Disley is the CEO and an investor at Mogrify, a pre-clinical stage biotechnology company based in Cambridge, United Kingdom. Prior to joining Mogrify in 2019, he spent 11 years as the CEO of Horizon Discovery, scaling the gene editing startup to more than 500 employees and leading its £68.6 million initial public offering on the London AIM market in 2014. At Mogrify, he subsequently guided the biopharmaceutical firm through a $33 million Series A funding round to advance its in vivo cellular reprogramming therapies. Disley holds a PhD in Biotechnology from the University of Cambridge and operates as an active angel investor and advisor who has backed over 40 life sciences and technology startups, including Start Codon. His career focuses on scaling early-stage regenerative medicine and gene therapy platforms into publicly listed global enterprises.
Darrin Disley stands out as a highly respected investor and a pivotal leader within the biotechnology landscape, particularly through his involvement with Mogrify. As a key figure at Mogrify, a company at the forefront of cell therapy, Darrin plays an instrumental role in shaping its strategic direction and fostering its growth. His vision helps guide Mogrify's mission to develop novel cell therapies that have the potential to revolutionize treatment for a wide range of diseases.
His investment focus areas are deeply rooted in the life sciences and biotechnology sectors. Darrin Disley is particularly interested in companies and technologies that offer disruptive solutions in areas such as regenerative medicine, cell and gene therapy, and other advanced therapeutic platforms. He seeks out opportunities where scientific innovation meets significant market need, aiming to back ventures that can deliver substantial patient benefit and commercial success. His commitment extends to supporting the entire ecosystem of biotech innovation, from early-stage research to commercialization.
Darrin Disley's career background is marked by a strong track record of leadership and success in building and scaling high-growth technology and life science companies. He has a proven ability to identify promising scientific breakthroughs and translate them into viable business opportunities. His experience encompasses various executive and board roles, where he has consistently demonstrated strategic acumen in fundraising, corporate development, and operational excellence. This extensive background provides him with a unique perspective on the challenges and opportunities within the biotech industry, enabling him to provide invaluable guidance to the companies he supports.
While specific external notable investments are not publicly detailed, Darrin Disley's most significant 'investment' is arguably his deep involvement and leadership at Mogrify. His strategic input, ability to attract capital, and guidance in navigating the complex regulatory and commercial landscapes are crucial to Mogrify's progress. Under his influence, Mogrify continues to push the boundaries of cell therapy, aiming to make a profound impact on global health. His work at Mogrify exemplifies his dedication to fostering innovation that can lead to life-changing medical advancements.
Darrin Disley is a prominent investor and a key leader at Mogrify, a pioneering cell therapy company. He is known for his expertise in the biotechnology and life sciences sectors, driving strategic growth and innovation.
Darrin Disley primarily invests in the life sciences and biotechnology sectors. His focus areas include regenerative medicine, cell and gene therapy, and other advanced therapeutic platforms that offer innovative healthcare solutions.
Darrin Disley works at Mogrify, a leading company specializing in cell therapy. He holds a significant leadership role within the organization, contributing to its strategic direction and growth.
